News
Ferrer’s R&D work focuses on neurological and pulmonary diseases, and the Spanish pharma has bought into ALS assets in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback